Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;79(7):937-945.
doi: 10.1007/s00228-023-03501-8. Epub 2023 May 15.

Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database

Laëtitia Gosselin  1   2 , Ana-Maria Vilcu  3 , Cécile Souty  3 , Olivier Steichen  3   4 , Titouan Launay  3 , Cécile Conte  5 , Béatrice Saint-Salvi  6 , Clément Turbelin  3 , Marianne Sarazin  3 , Thierry Blanchon  3 , Thomas Hanslik  3   7   8 , Maryse Lapeyre-Mestre  5 , Louise Rossignol  3   9
Affiliations
Free article

Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database

Laëtitia Gosselin et al. Eur J Clin Pharmacol. 2023 Jul.
Free article

Abstract

Purpose: Pharmacokinetic interactions exist between apixaban or rivaroxaban, and CYP3A4 and P-glycoprotein inhibitors such as amiodarone, verapamil and diltiazem. We aimed to estimate the prevalence of exposure to this drug-drug association (DDA) and to assess the bleeding risk associated in patients with atrial fibrillation (AF).

Methods: We conducted a cohort study using a representative 1/97th sample of the French healthcare insurance database between 2014 and 2019. Patients with AF receiving apixaban or rivaroxaban were included and followed-up until hospitalization for bleeding, death, discontinuation of apixaban or rivaroxaban, exposure to strong CYP3A4 inhibitor, or until December 31st 2019, whichever came first. Primary outcome was hospitalization for bleeding registered as primary diagnosis. The association between the exposure to the DDA and hospitalization for bleeding was evaluated as a time-dependent variable in Cox model.

Results: Between 2014 and 2019, the AF population under apixaban or rivaroxaban represented 10,392 patients. During the study period, the annual average prevalence of DDA exposure in this population was 38.9%. Among the 10,392 patients, 223 (2.1%) were hospitalized for bleeding, of which 75 (33.6%) received the association and 148 (66.4%) received apixaban or rivaroxaban alone. There was no association between DDA exposure and risk of hospitalization for bleeding (aHR = 1.19, [95% CI: 0.90, 1.58]). Age (HR 1.03 [1.02, 1.05]) and male gender (HR 1.72 [1.28, 2.30]) were associated with an increased risk of hospitalization for bleeding.

Conclusion: Exposure to antiarrhythmic drugs was not associated with an increased risk of hospitalization for bleeding in patients with AF under rivaroxaban or apixaban.

Keywords: Adverse drug reactions; Anti-arrhythmia agents; Anticoagulants; Drug interactions; Pharmacovigilance.

PubMed Disclaimer

References

    1. Hindricks G, Potpara T, Dagres N et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42:373–498. https://doi.org/10.1093/eurheartj/ehaa612 - DOI - PubMed
    1. Guide parcours de soins: Fibrillation atriale Février 2014. https://www.has-sante.fr/upload/docs/application/pdf/2014-05/guide_pds_f... . Accessed 29 Mar 2021
    1. Hellwig T, Gulseth M (2013) Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother 47:1478–1487. https://doi.org/10.1177/1060028013504741 - DOI - PubMed
    1. Hanigan S, Das J, Pogue K et al (2020) The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-020-02037-3 - DOI - PubMed
    1. Zhang Y, Souverein PC, Gardarsdottir H et al (2020) Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case–control study. Br J Clin Pharmacol 86:1150–1164. https://doi.org/10.1111/bcp.14227 - DOI - PubMed - PMC